Psoriatic Arthritis - Pipeline Review, H1 2015

Description: Psoriatic Arthritis - Pipeline Review, H1 2015

Summary

This, ‘Psoriatic Arthritis - Pipeline Review, H1 2015’, provides an overview of the Psoriatic Arthritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Psoriatic Arthritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Psoriatic Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Psoriatic Arthritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction

REPORT COVERAGE
Psoriatic Arthritis Overview
Therapeutics Development
Pipeline Products for Psoriatic Arthritis - Overview
Pipeline Products for Psoriatic Arthritis - Comparative Analysis
Psoriatic Arthritis - Therapeutics under Development by Companies
Psoriatic Arthritis - Therapeutics under Investigation by Universities/Institutes
Psoriatic Arthritis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Psoriatic Arthritis - Products under Development by Companies
Psoriatic Arthritis - Products under Investigation by Universities/Institutes
Psoriatic Arthritis - Companies Involved in Therapeutics Development
AbbVie Inc.
AbGenomics International, Inc.
Alder Biopharmaceuticals Inc.
Amgen Inc.
Avesthagen Limited
Biocon Limited
Bristol-Myers Squibb Company
Celgene Corporation
Celtrion, Inc.
Coherus BioSciences, Inc.
Covagen AG
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
Genor BioPharma Co., Ltd.
Inbiopro Solutions Pvt. Ltd.
Innovent Biologics, Inc.
Johnson & Johnson
Kineta, Inc.
Mabion SA
Momenta Pharmaceuticals, Inc.
Novartis AG
Oncobiologics, Inc.
Panacea Biotec Limited
Pfizer Inc.
Sandoz International GmbH
Swedish Orphan Biovitrum AB
Therapeutic Proteins International, LLC
UCB S.A.
Psoriatic Arthritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abatacept (recombinant) - Drug Profile
AbGn-168H - Drug Profile
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2015
Psoriatic Arthritis - Pipeline by AbbVie Inc., H1 2015
Psoriatic Arthritis - Pipeline by AbGenomics International, Inc., H1 2015
Psoriatic Arthritis - Pipeline by Alder Biopharmaceuticals Inc., H1 2015
Psoriatic Arthritis - Pipeline by Amgen Inc., H1 2015
Psoriatic Arthritis - Pipeline by Avesthagen Limited, H1 2015
Psoriatic Arthritis - Pipeline by Biocon Limited, H1 2015
Psoriatic Arthritis - Pipeline by Bristol-Myers Squibb Company, H1 2015
Psoriatic Arthritis - Pipeline by Celgene Corporation, H1 2015
Psoriatic Arthritis - Pipeline by Celltrion, Inc., H1 2015
Psoriatic Arthritis - Pipeline by Coherus BioSciences, Inc., H1 2015
Psoriatic Arthritis - Pipeline by Covagen AG, H1 2015
Psoriatic Arthritis - Pipeline by Eli Lilly and Company, H1 2015
Psoriatic Arthritis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Psoriatic Arthritis - Pipeline by Genor BioPharma Co., Ltd., H1 2015
Psoriatic Arthritis - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015
Psoriatic Arthritis - Pipeline by Innovent Biologics, Inc., H1 2015
Psoriatic Arthritis - Pipeline by Johnson & Johnson, H1 2015
Psoriatic Arthritis - Pipeline by Kineta, Inc., H1 2015
Psoriatic Arthritis - Pipeline by Mabion SA, H1 2015
Psoriatic Arthritis - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015
Psoriatic Arthritis - Pipeline by Novartis AG, H1 2015
Psoriatic Arthritis - Pipeline by Oncobiologics, Inc., H1 2015
Psoriatic Arthritis - Pipeline by Panacea Biotec Limited, H1 2015
Psoriatic Arthritis - Pipeline by Pfizer Inc., H1 2015
Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H1 2015
Psoriatic Arthritis - Pipeline by Swedish Orphan Biovitrum AB, H1 2015
Psoriatic Arthritis - Pipeline by Therapeutic Proteins International, LLC, H1 2015
Psoriatic Arthritis - Pipeline by UCB S.A., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Psoriatic Arthritis Therapeutics - Recent Pipeline Updates, H1 2015
Psoriatic Arthritis - Dormant Projects, H1 2015
Psoriatic Arthritis - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Psoriatic Arthritis, H1 2015
Number of Products under Development for Psoriatic Arthritis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Psoriatic Arthritis - Pipeline Review, H1 2015
Web Address: http://www.researchandmarkets.com/reports/3293089/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
</tbody>
</table>
| Bank Address   | Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World